Search

Search Constraints

You searched for: Author/Creator Shusterman, Suzanne

Search Results

1. PDCT-13. ENTRECTINIB IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS. (11th November 2019)

2. Unrealistic parental expectations for cure in poor‐prognosis childhood cancer. Issue 2 (4th October 2019)

3. Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. Issue 11 (12th August 2021)

4. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. Issue 31 (1st November 2021)

5. Efficacy of post‐induction therapy for high‐risk neuroblastoma patients with end‐induction residual disease. Issue 15 (6th June 2022)

6. The use of interval‐compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. Issue 10 (19th July 2020)

7. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Issue 10 (8th April 2022)

8. HGG-01. ENTRECTINIB IN RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS: UPDATED DATA IN CHILDREN AND ADOLESCENTS. (4th December 2020)

9. Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. (9th March 2021)